Ex-Merck cancer R&D chief Gilliland takes the helm at Fred Hutch

Gary Gilliland

The Fred Hutchinson Cancer Research Center has tapped well-known drug investigator Gary Gilliland to become its new president. Beginning on the first work day in January, Gilliland, who recently completed a stretch at Merck ($MRK) as head of oncology drug research, will take the helm of one of the country's top cancer research institutes. Among other things, the Hutch has played a leading role in launching the CAR-T and TCR player Juno, which is now going public. Gilliland's lengthy resume includes a professorship at Harvard University and a stint at the Howard Hughes Medical Institute. And he says the timing is right to focus on new ways to cure cancer. "This is the perfect time and perfect place to develop curative approaches for cancer," said Gilliland, a physician-scientist. "Everything I've done in my career has pointed here." Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.

The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.